Kestra Medical Technologies, Inc.

Kestra Medical Technologies, based in the US, develops innovative medical devices to combat Sudden Cardiac Arrest through advanced wearable technology and comprehensive patient management solutions. Kestra Medical Technologies specializes in addressing Sudden Cardiac Arrest (SCA) with its flagship product, the ASSURE® system. Established in 2014, the company is headquartered in Kirkland, US. It has raised a total of USD 196.

00 mn across multiple funding rounds, with a recent round yielding USD 196. 00 mn led by investors including Ally Bridge Group and Bain Capital. The company has completed a total of 3 deals, with the most recent deal occurring on February 26, 2025. Kestra Medical Technologies specializes in the development and provision of advanced medical solutions designed to address the critical issue of Sudden Cardiac Arrest (SCA).

Their core product, the ASSURE® system, is a state-of-the-art Wearable Cardioverter Defibrillator (WCD) that incorporates integrated sensing, autonomous detection, and effective defibrillation therapy. This non-invasive device continuously monitors patients at elevated risk of SCA, particularly those with heart failure or low left ventricular ejection fraction (LVEF). The ASSURE® system is complemented by the Kestra CareStation™ remote patient data platform, which facilitates comprehensive management of at-risk cardiac patients, and the ASSURE patient application that actively engages users in their recovery process. Kestra's offerings target primarily the U.

S. market, catering to healthcare providers, hospitals, and directly to patients with specific cardiac conditions. Kestra Medical Technologies generates revenue through a multifaceted transaction model primarily involving direct sales and partnerships with healthcare providers. The company’s flagship product, the ASSURE® system, is offered under a subscription model that includes device rental and ongoing support through the Kestra CareStation™ platform.

Healthcare institutions typically engage in direct transactions for the acquisition of these devices, while patients may access services through their healthcare providers, ensuring a streamlined approach to cardiac care management. The pricing structure aligns with the clinical needs of the target patients, providing healthcare systems with essential tools to enhance patient outcomes while addressing the pressing issue of SCA. In February 2025, Kestra Medical Technologies, Inc. plans to utilize the USD 201.

99 mn raised in its recent IPO to further develop innovative medical solutions and expand its market presence. The company aims to enhance the ASSURE® system and introduce new products targeting Sudden Cardiac Arrest, while also expanding into additional geographic regions including Europe and Asia by 2026. The successful IPO positions Kestra to leverage its recent funding to scale operations and enhance its technology, ensuring a robust approach to cardiac care management.